PHARMA IMPEX
ActiveFinancials · financial year 2024, micro format
2025 annual accounts not yet filed, deadline passed on 31 July 2026 The financial year closed on 31 December 2025. The accounts are due at the latest 7 months after the close (Companies Code art. 3:10). Source: NBB filings, as of 2 November 2026.
Annual accounts 2024 filed on 25-08-2025 PDF all 4 filings
2021 to 2024, 4 financial years
The operating result for 2024 is a loss of €3,065, smaller than the loss of €5,613 in 2023.
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
The EBIT margin is the share of each euro of turnover left from operations. The return on assets is what the assets earn.
The higher the solvency, the better the company absorbs a setback.
A ratio above 1 means the short-term assets cover the short-term debts.
Use the arrow keys on the chart for the figures per year.
The sector band is the middle half of the companies in Retail trade (NACE 47). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30. The dashed line is the median. There is a sector band for net result, equity, total assets, working capital, solvency, current ratio and return on assets (ROA).
Investments
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Financial fixed assets | €135 | - | - | - |
Source: notes to the 2021 to 2024 annual accounts (statement of fixed assets)
| Line | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | €506 | €2,552 | -€3,058 | - |
| Other operating charges640/8 | €50 | - | - | €387 | - |
| Gross operating margin9900 | €1,699 | -€6,575 | -€3,061 | -€5,736 | ▼ 87.4% |
| Operating profit (loss)9901 | €1,649 | -€7,081 | -€5,613 | -€3,065 | ▲ 45.4% |
| Financial income75/76B | - | - | €0 | €0 | ▲ 300% |
| Recurring financial income75 | - | - | €0 | €0 | ▲ 300% |
| Financial charges65/66B | €36 | €123 | €347 | €153 | ▼ 55.8% |
| Recurring financial charges65 | €36 | €123 | €347 | €153 | ▼ 55.8% |
| Profit (loss) for the period before taxes9903 | €1,613 | -€7,204 | -€5,960 | -€3,218 | ▲ 46.0% |
| Income taxes67/77 | €353 | - | - | €0 | - |
| Profit (loss) for the period9904 | €1,260 | -€7,204 | -€5,960 | -€3,218 | ▲ 46.0% |
| Profit (loss) for the period to be appropriated9905 | €1,260 | -€7,204 | -€5,960 | -€3,218 | ▲ 46.0% |
| Line | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €16,945 | €8,040 | €14,359 | €9,218 | ▼ 35.8% |
| Fixed assets21/28 | €135 | €0 | - | - | - |
| Financial fixed assets28 | €135 | €0 | - | - | - |
| Current assets29/58 | €16,810 | €8,040 | €14,359 | €9,218 | ▼ 35.8% |
| Stocks and contracts in progress3 | €11,722 | €5,958 | €2,799 | €2,799 | = |
| Stocks30/36 | €11,722 | €5,958 | €2,799 | €2,799 | = |
| Amounts receivable within one year40/41 | €1,324 | €777 | €10,881 | €6,386 | ▼ 41.3% |
| Trade receivables40 | €1,084 | €170 | €10,881 | €6,242 | ▼ 42.6% |
| Other amounts receivable41 | €241 | €608 | - | €144 | - |
| Cash at bank and in hand54/58 | €3,631 | €1,214 | €679 | €33 | ▼ 95.2% |
| Deferred charges and accrued income490/1 | €132 | €91 | - | - | - |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €16,945 | €8,040 | €14,359 | €9,218 | ▼ 35.8% |
| Equity10/15 | €3,260 | -€3,944 | -€9,904 | -€13,123 | ▼ 32.5% |
| Contributions10/11 | €2,000 | €2,000 | €2,000 | €2,000 | = |
| Reserves13 | €1,000 | €1,000 | €1,000 | €1,000 | = |
| Distributable reserves133 | €1,000 | €1,000 | €1,000 | €1,000 | = |
| Profit (loss) carried forward14 | €260 | -€6,944 | -€12,904 | -€16,123 | ▼ 24.9% |
| Amounts payable17/49 | €13,684 | €11,985 | €24,263 | €22,340 | ▼ 7.9% |
| Amounts payable within one year42/48 | €13,684 | €11,985 | €24,263 | €22,340 | ▼ 7.9% |
| Trade debts44 | €11,028 | €6,798 | €15,055 | €6,277 | ▼ 58.3% |
| Suppliers440/4 | €11,028 | €6,798 | €15,055 | €6,277 | ▼ 58.3% |
| Advances received on contracts in progress46 | - | - | - | €7,439 | - |
| Taxes, remuneration and social security45 | €353 | €353 | €1,014 | - | - |
| Taxes450/3 | €353 | €353 | €1,014 | - | - |
| Other amounts payable47/48 | €2,303 | €4,833 | €8,194 | €8,625 | ▲ 5.3% |
| Line | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €1,260 | -€7,204 | -€5,960 | -€3,218 | ▲ 46.0% |
| Operating cash flow (approximation) | €1,260 | -€7,204 | -€5,960 | -€3,218 | ▲ 46.0% |
| Investment in fixed assets (approximation) | - | €135 | - | - | - |
| Change in cash | - | -€2,417 | -€536 | -€646 | ▼ 20.7% |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 6,008 companies had the same profile as PHARMA IMPEX has now. Two years later, 7.9% had gone bankrupt and 83.0% were still going.
- Micro
- 5 to 10 years old
- negative equity
- a loss of 10% of the balance sheet or more
Another 0.8% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of PHARMA IMPEX itself: 8.8% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,008 companies, not a prediction for PHARMA IMPEX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.